Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Leukocyte Biology|April 26, 2003
Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(alpha)i proteins and enhances engraftment of competitive, repopulating stem cellsHal E Broxmeyer, Lisa Kohli, Chang H Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2010
Methylation of histone H3 lysine 36 enhances DNA repair by nonhomologous end-joiningSheema Fnu, Elizabeth A Williamson, Leyma P De Haro, et al.
Cancer Research|October 24, 2012
Targeting the transposase domain of the DNA repair component Metnase to enhance chemotherapyElizabeth A Williamson, Leah Damiani, Andrei Leitao, et al.
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Cancer Chemotherapy and Pharmacology|January 19, 2017
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancerJeffrey R Infante, Amita Patnaik, Claire F Verschraegen, et al.
Nucleic Acids Research|November 12, 2023
TATDN2 resolution of R-loops is required for survival of BRCA1-mutant cancer cellsAruna S Jaiswal, Arijit Dutta, Gayathri Srinivasan, et al.
JCO Precision Oncology|December 3, 2024
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient NeoplasmsThomas J George, Ji-Hyun Lee, David L DeRemer, et al.
Cancer|August 3, 2025
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b studyMohammed M Milhem, Yousef Zakharia, Diwakar Davar, et al.
The New England Journal of Medicine|April 21, 2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A Postow, Jason Chesney, Anna C Pavlick, et al.
Pageof 4